Bid date, 2026-10-20
Auction date 2026-10-20
Settlement date 2026-10-21
Maturity Date 2026-10-28
Nominal amount 471 billion SEK
Interest rate 1.75 %
Bid times 09.30-10.00 (CET/CEST) on the Bid date
Bids are made to phone number 08-696 69 70
Confirmation of bids to e-mail rbcert@riksbank.se
The lowest accepted bid volume 1 million SEK
The highest accepted bid volume 471 billion SEK
Allocation Time 10.15 (CET/CEST) on the Bid date
Projected minimum liquidity surplus during the term 471 billion SEK
Expected excess liquidity at full allotment 0 billion SEK

Stockholm, 2026-10-20

Tryg Forsikring A/S, rated Aa3 by Moody’s, has mandated Danske Bank and Nordea as Joint Lead Managers to arrange a Global Investor Call (GIC) and a series of virtual investor meetings today, 20 October 2026, and to explore subsequent issuance of one or more Tier 2 Capital Notes. A NOK- and/or SEK-denominated FRN with a targeted 30NC5.25-year maturity may follow, subject to market conditions. The Notes are expected to be rated A2 by Moody’s.

In connection with the contemplated issuance of the Notes, the Issuer is contemplating to purchase some or all of its outstanding SEK 1,300,000,000 Floating Rate Tier 2 Capital Notes with ISIN DK0030488101 (the Existing Notes). Any purchase by the Issuer of Existing Notes will be executed in the absolute and sole discretion and determination of the Issuer and any such purchase shall be conditional upon (i) the successful completion of the issuance and settlement of the Notes, (ii) receipt by the Issuer of the proceeds of the issuance of the Notes, (iii) that the Issuer’s purchase of the Existing Notes is funded out of the proceeds of the Notes and (iv) the satisfaction of each of the Redemption and Purchase Conditions as set out and as defined in the terms and conditions of the Existing Notes (together the Purchase Conditions). The purchase price for any such purchase of Existing Notes will be announced when determined by the Issuer, expectedly in conjunction with the announcement of pricing of the contemplated issue of the Notes.

MIFID II product governance / Professional investors and eligible counterparties only target market / No PRIIPs KID: The target investors of the Notes are only eligible counterparties and professional clients (all distribution channels). No packaged retail and insurance-based investment products (“PRIIPs”) key information document (“KID”) has been prepared as the Notes are not available to retail investors in the European Economic Area or the United Kingdom.

Additional information:
For further information, visit tryg.com tryg.com or contact:

Head of Financial Reporting, Gianandrea Roberti at +45 20 18 82 67 or gianandrea.roberti@tryg.dk
Head of Investor Relations, Robin H. Løfgren at +45 41 86 25 88 or robin.loefgren@tryg.dk

This announcement is for information purposes only and is not intended to, and does not, constitute or form part of any offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of, any securities, or the solicitation of any vote or approval in any jurisdiction pursuant to the Transaction or otherwise in any jurisdiction in which such offer, invitation or solicitation is unlawful.

This announcement does not constitute a prospectus, prospectus equivalent document or an exempted document.

This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America. This announcement is not an offer of securities for sale into the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933 (the “US Securities Act”), as amended, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of securities is being made in the United States.

About Tryg
Tryg is one of the largest insurance companies in the Nordic region with activities in Denmark, Norway and Sweden. Tryg provides peace of mind and value for more than 6 million customers on a daily basis. Tryg A/S is listed on NASDAQ Copenhagen and approximately 50% of the shares are held by TryghedsGruppen smba. TryghedsGruppen, annually, contributes around DKK 775m to peace of mind purposes via TrygFonden.

Notice to U.S. investors
This announcement does not constitute an offer to sell, or a solicitation of offers to purchase or subscribe for, securities in the United States. The securities referred to herein have not been, and will not be, registered under the US Securities Act, and may not be offered, exercised or sold in the United States absent registration or an applicable exemption from registration requirements.

Cautionary note about forward-looking statements
This announcement (including any information incorporated by reference in this announcement), oral statements made regarding the Transaction, and other information published by Tryg Forsikring A/S contain statements which are, or may be deemed to be, “forward-looking statements”. Forward looking statements are prospective in nature and are not based on historical facts, but rather on current expectations and projections of the management of Tryg Forsikring A/S about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements.

Forward looking statements often use words such as “believe”, “expect”, “estimate”, “intend”, “anticipate” and words of a similar meaning, and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would”, “might” or “will” be taken, occur or be achieved (or, in each case, their negative or other variations). You should not place undue reliance on these forward looking statements, which reflect the current views of Tryg Forsikring A/S, are subject to risks and uncertainties about Tryg Forsikring A/S and are dependent on many factors, some of which are outside of Tryg Forsikring A/S’ control. There are important factors, risks and uncertainties that could cause actual outcomes and results to be materially different. Except as required by law, Tryg Forsikring A/S undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Attachment

New physically backed products broaden European investor access to decentralised perpetual futures and privacy-focused AI infrastructure via standard brokerage accounts

ZÜRICH, 20 October 2026 – 21shares, a global leader in digital asset exchange-traded products (ETPs), today announced the launch of two new products: the 21shares Lighter ETP (ticker: LIHT) and the 21shares Venice Token ETP (ticker: VENC).

Both products are physically backed ETPs designed to provide European investors with seamless exposure to two rapidly emerging crypto sectors: decentralised perpetual trading and private artificial intelligence infrastructure. Listed on major European venues, LIHT and VENC trade through conventional investment channels.

Product Ticker ISIN Exchange Currency Fee
21shares Lighter ETP LIHT CH1615641755 Deutsche Börse Xetra EUR, USD 2.50%
21shares Venice Token ETP VENC CH1614108301 SIX Swiss Exchange USD 2.50%


21shares Lighter ETP (ticker: LIHT)

The 21shares Lighter ETP offers exposure to Lighter (LIT), the native token of a high-performance decentralised exchange specialising in perpetual futures across crypto, foreign exchange, equities, and commodities. Lighter utilises zero-knowledge technology to ensure fully verifiable order matching and liquidations.

  • Economic value accrual: Lighter directs platform revenue toward LIT token buybacks and permanent burns, directly linking exchange activity to token demand.
  • Broader market reach: beyond crypto, Lighter supports trading across traditional asset classes and integrates directly with major consumer platforms like Robinhood Wallet.

21shares Venice Token ETP (ticker: VENC)

The 21shares Venice Token ETP provides targeted exposure to Venice Token (VVV), the core asset powering Venice, a privacy-first AI platform built to deliver powerful AI inference without exposing or retaining user data, sensitive code, or corporate records.

  • Private AI commercialisation: Venice operates an OpenAI-compatible API model that serves developers and enterprises requiring zero-data-retention AI processing.
  • Improving tokenomics: Venice implements a token burn mechanism using subscription revenue, alongside a scheduled 86% reduction in annual VVV emissions to capture long-term platform value.

Directly purchasing and holding crypto tokens requires opening specialised exchange accounts, managing private key security, and navigating operational risk. The 21shares ETP wrapper eliminates these barriers by providing physically backed exposure within a familiar exchange-traded structure available on the most widely adopted brokers and investment platforms.

“Lighter brings a high-performance, fee-generating perpetual futures DEX to traditional accounts, while Venice delivers exposure to the booming private AI sector where data privacy and compute economics meet,” said Jasmin Muelhaupt, Head of Financial Product Development at 21shares. “With the launch of LIHT and VENC, we continue to bridge the gap between frontier protocols and traditional investment portfolios through familiar physically backed structures.”

For more information on the 21shares Lighter ETP and the 21shares Venice Token ETP, please visit www.21shares.com.

Notes to editors

About 21shares

21shares is one of the world’s leading cryptocurrency exchange traded product (ETP) providers and offers one of the largest suites of crypto ETPs in the market. The company was founded to make cryptocurrency more accessible to investors, and to bridge the gap between traditional finance and decentralised finance. 21shares listed the world’s first physically-backed crypto ETP in 2018, building an eight-year track record of creating crypto ETPs that are listed on some of the biggest, most liquid securities exchanges globally. Backed by a specialised research team, proprietary technology, and deep capital markets expertise, 21shares delivers innovative and cost-efficient investment solutions.

21shares is a subsidiary of FalconX, one of the world’s largest digital asset prime brokers. 21shares maintains independent operations from FalconX while strategically leveraging the resources and reach of FalconX to accelerate its mission and unlock new growth. For more information, please visit www.21shares.com.

Contact: audrey.belloff@21shares.com

DISCLAIMER

This document is not an offer to sell or a solicitation of an offer to buy or subscribe for securities of 21Shares AG in any jurisdiction. Neither this document nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever or for any other purpose in any jurisdiction. Nothing in this document should be considered investment advice.

This document and the information contained herein are not for distribution in or into (directly or indirectly) the United States, Canada, Australia or Japan or any other jurisdiction in which the distribution or release would be unlawful.

This document does not constitute an offer of securities for sale in or into the United States, Canada, Australia or Japan. The securities of 21Shares AG to which these materials relate have not been and will not be registered under the United States Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There will not be a public offering of securities in the United States. Neither the US Securities and Exchange Commission nor any securities regulatory authority of any state or other jurisdiction of the United States has approved or disapproved of an investment in the securities or passed onG the accuracy or adequacy of the contents of this presentation. Any representation to the contrary is a criminal offence in the United States.

Within the United Kingdom, investments in crypto exchange-traded notes (cETNs) are classified by the Financial Conduct Authority (FCA) as Restricted Mass Market Investments (RMMIs) and are considered high-risk and complex products. You should not invest unless you’re prepared to lose all the money invested. cETNs are highly volatile, and you are unlikely to be protected if something goes wrong. These products are not covered by the UK Financial Services Compensation Scheme (FSCS) or the Financial Ombudsman Service (FOS).  This is not a recommendation to invest. Any investment decision should be based solely on the official offering documents of the Issuers (such as the approved base prospectus and final terms), published in accordance with applicable law.

Exclusively for potential investors in any EEA Member State that has implemented the Prospectus Regulation (EU) 2017/1129 the Issuer’s Base Prospectus (EU) is made available on the Issuer’s website under www.21Shares.com.

The approval of the Issuer’s Base Prospectus (EU) should not be understood as an endorsement by the SFSA of the securities offered or admitted to trading on a regulated market. Eligible potential investors should read the Issuer’s Base Prospectus (EU) and the relevant Final Terms before making an investment decision in order to understand the potential risks associated with the decision to invest in the securities. You are about to purchase a product that is not simple and may be difficult to understand.

This document constitutes advertisement within the meaning of the Prospectus Regulation (EU) 2017/1129 and the Swiss Financial Services Act (the “FinSA”) and not a prospectus. The 2026 Base Prospectus of 21Shares AG has been deposited pursuant to article 54(2) FinSA with SIX Exchange Regulation AG in its function as Swiss prospectus review body within the meaning of article 52 FinSA. The 2026 Base Prospectus and the key information document for any products may be obtained at 21Shares AG’s website (https://21shares.com/ir/prospectus or https://21shares.com/ir/kids).

###

Nanterre, 20 October 2026

VINCI wins a contract for a data center in the Iberian Peninsula

  • Construction of a cooling plant for a major data center campus
  • A €165 million contract value
  • Strengthening the Group’s position in the digital infrastructure portfolio

Cobra IS has been awarded a new contract for the construction of a cooling plant for a major data center campus in the Iberian Peninsula.

The project, a €165 million contract value, includes the delivery of mechanical, electrical, and plumbing (MEP) installations for 126 dry coolers. They will cool the equivalent of 200 MW of computing capacity and play a critical role in keeping the campus operating reliably.

Cobra IS is currently in the process of bidding for further phases of this data center campus worth several billion euros in total.

This new contract further reinforces VINCI’s position as a strategic partner for the delivery of large-scale digital infrastructure. Driven by increasing demand for artificial intelligence, this market is booming. The VINCI Group aims at playing a key-role in this market, especially in France and some Asian countries.

VINCI’s revenue in the digital infrastructure market was €7 billion in 2025.

About VINCI
VINCI is a world leader in concessions, energy solutions and construction, employing 294,000 people in more than 120 countries. We design, finance, build and operate infrastructure and facilities that help improve daily life and mobility for all. Because we believe in all-round performance, above and beyond economic and financial results, we are committed to operating in an environmentally and socially responsible manner. And because our projects are in the public interest, we consider that reaching out to all our stakeholders and engaging in dialogue with them is essential in the conduct of our business activities. VINCI’s ambition is to create long-term value for its customers, shareholders, employees, partners and society in general. www.vinci.com

This press release is an official information document of the VINCI Group.

PRESS CONTACT
VINCI Press Department
Tel: +33 (0)1 57 98 62 88
media.relations@vinci.com

 

Attachment

Paris

Quadient (Euronext Paris: QDT), a global automation platform powering secure and sustainable business connections, announced today that it has been named a Leader in the IDC MarketScape: Worldwide Intelligent Customer Communication Management 2026 Vendor Assessment (IDC #US54131626, September 2026). Quadient believes its recognition as a Leader reflects the breadth, depth and proven capabilities of Quadient’s customer communications management solution, Quadient Inspire.

According to Amy Machado, research director at IDC: “As customer communications management evolves into AI-powered customer experience orchestration, Quadient differentiates through its innovation, deployment flexibility, and commitment to helping organizations deliver meaningful customer interactions. By combining AI-driven customer communications, customer journey mapping, communication design, governance, and support for SaaS, hybrid, and on-premises environments, Quadient enables enterprises to deliver personalized, compliant, and omnichannel experiences at scale. This combination of capabilities positions Quadient as a compelling choice for organizations modernizing customer communications, strengthening customer engagement, and accelerating digital transformation.”

Quadient Inspire covers the full communications lifecycle across digital, interactive, print and forms-based experiences from a single platform, with integrated journey mapping and AI capabilities that help users create and optimize content, streamline workflows, enhance personalization and strengthen governance. With its any-prem strategy, Quadient gives customers the flexibility to deploy on-premises, on IaaS, on PaaS or as SaaS, and change their deployment model without the complexity of migrating to a different platform.

The IDC MarketScape noted Quadient’s key strengths, including “Support resources: Customers we spoke with gave Quadient high marks for its support, including technical support and ongoing communication. Quadient fosters an active user community through extensive support resources, including access to samples, sandboxes, reference applications, and training.”

“I believe being named a Leader by IDC MarketScape reflects our commitment to helping organizations connect data, governance and AI on a single platform to create hyper-personalized communications that are easier to manage,” said Lilac Schoenbeck, senior vice president, product for Quadient Digital. “In today’s world, the ability to execute is what turns vision into meaningful customer outcomes. We believe this recognition underscores the breadth and depth of Quadient’s ability to deliver for customers today, while continuing to invest in the innovations that will drive future success.”

To learn more about Quadient Inspire, visit www.quadient.com/en-us/customer-communications.

About IDC MarketScape

IDC MarketScape vendor assessment model is designed to provide an overview of the competitive fitness of technology and service suppliers in a given market. The research utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each supplier’s position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of technology suppliers can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective suppliers.

About Quadient
Quadient designs and builds human-centered, AI-driven automation solutions for business communications. Our software empowers hundreds of thousands of customers to create, deliver, and manage world-class communications with speed and ease. From financial automation and customer communications to mail and parcel management, Quadient reduces friction and waste so customers can focus on growth and customer connections. Quadient is listed on Euronext Paris (QDT) and part of the CAC® Mid & Small and CAC Technology indexes. Make room for the remarkable at quadient.com.

Contacts
Joe Scolaro, Quadient
+1 203-301-3673
j.scolaro@quadient.com  

Kaitlynn Cooney, Walker Sands   
PR Director   
quadientpr@walkersands.com   

Attachment

InstallatørGruppen Switzerland announces the acquisition of Steinmann Haustechnik AG, headquartered in Baar (Canton of Zug). With the acquisition, InstallatørGruppen expands its presence in the economically strong Central Switzerland region and increases the number of group members in Switzerland to 6 companies.

Steinmann Haustechnik AG looks back on a company history spanning over 140 years and is a recognised specialist in plumbing and heating installations in the region. The family business was founded in 1881 and generates annual revenues of over CHF 12 million (DKK 96 million).

Steinmann Haustechnik AG will continue to operate under its own name and will be led by Philippe Steinmann, owner-manager in the fifth family generation. At his side is his wife Katja Steinmann as Head of Administration.

Owner-manager Philippe Steinmann explains that Steinmann Haustechnik AG is a company that has always distinguished itself through its innovative strength and forward-looking approach. It was with this in mind that the entrepreneur decided to join InstallatørGruppen: “For 145 years, the Steinmann name has stood for quality craftsmanship in Central Switzerland. With InstallatørGruppen, we gain access to a strong network and new resources. This creates security for our employees and customers and opens up additional long-term perspectives for us.”

Andreas Weiss, CEO of InstallatørGruppen Switzerland, adds: “With Steinmann Haustechnik AG, we are gaining a family business with deep roots in Central Switzerland and an impressive, long-standing track record. To be able to welcome a company with such a long-standing tradition into our group is an honour and reinforces our commitment to combining the strengths of local entrepreneurship with the benefits of group membership.”

Including one previously announced transaction in Denmark, subject to regulatory approval, the total number of acquisitions across Denmark and Switzerland would increase to 50.

The acquisition does not change InstallatørGruppen’s financial outlook for 2026, as most recently confirmed in the interim report for the first half of 2026.

Contact details
Head of Communications
Morten Reedtz Kjellev
+45 2921 6999
mk@i-g.dk

Head of M&A and Investor Relations 
Maximillian Hjorth Beste
+45 2899 2846
mhb@i-g.dk

About InstallatørGruppen
InstallatørGruppen is a leading provider of multi-disciplinary technical installation services in Denmark and Switzerland. The Group comprises independent companies with a strong local presence and in-depth technical expertise. The companies within the Group offer solutions in the fields of plumbing, heating, ventilation/air conditioning, refrigeration and electrical systems, as well as in selected specialist areas such as sprinkler systems, energy optimisation, building automation, fibre-optic infrastructure and solar panel installations. The Group’s aim is to be a preferred partner for its customers in implementing the energy transition. InstallatørGruppen is listed on Nasdaq Copenhagen.

Presentation highlights new translational data evaluating plasma NfL and GFAP as biomarkers of neuroaxonal injury and neuroinflammation

ZUG, Switzerland, October 20, 2026 — Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology, today announced that new biomarker data from the Phase 2 ACUITY trial of Privosegtor will be featured in a late-breaking session at the 10th Joint ACTRIMS-ECTRIMS Meeting (MSToronto 2026), on October 21-23, 2026, in Toronto, Canada.

The presentation will unveil new analyses evaluating circulating neuroaxonal and neuroinflammatory biomarkers, specifically plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP), in patients with acute optic neuritis (ON). These translational endpoints provide critical insight into acute central nervous system injury cascades and the biological rationale underlying neuroprotection.

The presentation will provide congress attendees, clinical investigators, members of the neuro-ophthalmology and multiple sclerosis communities with an opportunity to hear directly from Professor Céline Louapre, the principal investigator of the ACUITY Phase 2 trial, and discuss the new findings during the session.

Details of Oculis’ presentation at the ACTRIMS-ECTRIMS joint meeting are as follows:

Presentation: Effect of Privosegtor on Plasma Neurofilament-Light and Glial Fibrillary Acidic Protein Levels in the Phase 2 ACUITY Trial in Optic Neuritis
Presenter: Céline Louapre, M.D., Ph.D., Pitié-Salpêtrière Hospital
Session: Late Breaking Abstracts
Presentation ID: P1507
Date/Time: Thursday, October 22, 2026; 4:30 – 6:30 p.m. EDT
Location: Metro Toronto Convention Centre

“Optic neuritis and demyelinating relapses represent a high-stakes clinical race against permanent neuro-axonal loss and irreversible functional deficits such as visual impairments,” said Riad Sherif, M.D., Chief Executive Officer of Oculis. “With no approved neuroprotective therapies currently available to protect retinal ganglion cells and their axons, which transmit visual signals from the eye to the brain, deep translational analyses are vital to advancing care. At ECTRIMS, Professor Céline Louapre will present objective plasma biomarker readouts from the Phase 2 ACUITY trial, offering key insights into the biological pathways of optic neuritis and the neuroprotective potential of Privosegtor. We invite the international clinical and scientific community to join us for this late-breaking presentation as we work to advance the next frontier of neuroprotection.”

Following the successful Phase 2 ACUITY trial, Privosegtor was granted Breakthrough Therapy designation from the FDA and Priority Medicines (PRIME) designation from the EMA.  Oculis’ PIONEER (Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research) program includes two registrational trials evaluating Privosegtor in patients with optic neuritis. The first trial, PIONEER-1, is currently enrolling patients with acute-onset ON across a broad population, including individuals with and without multiple sclerosis. Oculis plans to file an IND for Privosegtor in acute MS relapses. The Company will host an R&D Day on December 8, 2026, to provide updates on its differentiated late-stage pipeline, including Privosegtor and Licaminlimab.

– Ends –

About Privosegtor
Privosegtor, a novel peptoid small-molecule candidate that crosses the blood-brain and retinal barriers, has the potential to become the first neuroprotective therapy for optic neuritis (ON) and other neuro-ophthalmic and neuro-axonal diseases. Positive results from the ACUITY Phase 2 trial showed Privosegtor’s neuroprotective potential, as evidenced by improved visual function, corroborated by anatomical preservation of the retina, including the GCIPL and RNFL layers, and reduced neurofilament levels in the blood after an acute episode of optic neuritis. Consistent results were observed in animal models of glaucoma, optic neuritis, and multiple sclerosis (MS), where Privosegtor preserved retinal ganglion cells and was associated with improvements in mobility (clinical function disability) in the MS model.

Privosegtor has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) as well as Orphan Drug designation from both the FDA and the EMA for ON. Privosegtor is currently being evaluated in Oculis’ PIONEER (Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research) program, which includes two registrational trials in ON and one registrational trial in non-arteritic anterior ischemic optic neuropathy (NAION). Building on the ACUITY Phase 2 dataset in ON and constructive FDA pre-IND feedback, Oculis is also planning an IND submission for Privosegtor for the treatment of acute MS relapses.

Privosegtor is an investigational drug and has not received regulatory approval for commercial use in any country.

About Optic Neuritis

Optic Neuritis (ON) is a rare condition characterized by an acute inflammation of the optic nerve that can lead to permanent visual impairment. It affects up to 8 in 100,000 people worldwide with a U.S. annual incidence estimated to be >30,000 and often represents the first sign of multiple sclerosis1,2. It mainly occurs in adults between the age of 20 and 40 years and is more frequent in women (2:1)3. ON is a type of neuropathy (nerve disease) that happens when acute inflammation of the optic nerve affects the signals traveling from the eyes through the brain, causing pain, vision loss and other symptoms. The cells that make up the optic nerve have a lipid protective coating called a myelin sheath, which is preferentially damaged in ON. Without myelin, the optic nerve cells can’t send signals properly and axons can be irreversibly lost. To date there is no specific therapy approved for acute optic neuritis and the unmet needs remain for therapies that can prevent vision loss after an acute episode by reducing nerve cell permanent damage or death.


About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology. Oculis’ highly differentiated late-stage clinical pipeline focuses on two core product candidates. Privosegtor is a breakthrough neuroprotective candidate in the PIONEER program, which consists of studies intended to support registration plans for treatment of optic neuropathies, including optic neuritis (ON) and non-arteritic anterior ischemic optic neuropathy (NAION). Privosegtor also has potential to be developed for additional indications in other neuro-ophthalmic and neuro-axonal diseases. Licaminlimab is a novel, topical anti-TNFα in a registrational trial, and is being developed with a genotype-based approach for treating patients with dry eye disease (DED). Headquartered in Switzerland with operations in the U.S., Iceland and Switzerland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.
           
For more information, please visit: www.oculis.com

Oculis Contact
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com
mailto:

Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com

Media Relations
ICR Healthcare
Amber Fennell
oculis@icrhealthcare.com

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements and information. For example, statements regarding the potential benefits of the Company’s product candidates, including the potential for Privosegtor to become the first neuroprotection therapy for optic neuritis and its potential broad applicability across neurology, including in acute MS relapses, the initiation, enrollment, timing, progress and results of current and future clinical trials, Oculis’ research and development programs, regulatory and business strategy; Oculis’ future development plans; the timing or likelihood of regulatory filings and approvals; and statements about market opportunity, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Oculis’ control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Results of earlier stage clinical trials may not be replicated in subsequent clinical trials. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F and any other documents filed with the U.S. Securities and Exchange Commission (SEC). Copies of these documents are available on the SEC’s website, www.sec.gov. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

References:

  1. Martínez-Lapiscina EH, et al. (2014): Is the incidence of optic neuritis rising? Evidence from an epidemiological study in Barcelona (Spain) 2008-2012. J Neurol. 2014 Apr; 261(4): 759-767.
  2. Pérez-Cambrodí RJ, Gómez-Hurtado Cubillana A, Merino-Suárez ML, Piñero-Llorens DP, Laria-Ochaita C. Optic neuritis in pediatric population: a review in current tendencies of diagnosis and management. J Optom. 2014 Jul-Sep;7(3):125-30. 
  3. Sing Hayreh S. (2008): Nonarteritic anterior ischemic optic neuropathy: natural history of visual outcome. Ophthalmology. 2088 Feb;115(2):298-305.

Alm. Brand Group hereby publish consensus estimates prior to the announcement of the Q3 results.

Consensus estimates are also available via: almbrand.dk

Conference Call

Alm. Brand Group will report its Q3 2026 results on 28 October at around 07:30 CET and host a conference call with management at 11:00 CET on the day of release.

Dial in for analysts and investors (Conference ID: 463 676 395):

Denmark: +45 80 83 03 77

UK: +44 117 389 0104

USA: +1 585 542 9983

Contact

Please direct any questions regarding this announcement to:

Investors and equity analysts:                         

Mads Thinggaard – Head of Investor Relations & ESG – mobile no. +45 2025 5469                                                                                                         

Press:                                                                                           

Mikkel Luplau Schmidt – Head of Communications and Media Relations – mobile no. +45 2052 3883

Attachments

Bang & Olufsen A/S has, pursuant to the Danish Capital Markets Act, received a major shareholder notification from UBS Group AG.

  • As per 14 October 2026, UBS Group AG’s holding of shares and voting rights pursuant to section 38 of the Danish Capital Markets Act, as well as other financial instruments pursuant to section 39(2), was below 5 percent of the total share capital and voting rights in Bang & Olufsen A/S.
  • As per 15 October 2026, UBS Group AG’s holding of shares and voting rights pursuant to section 38 of the Danish Capital Markets Act, as well as other financial instruments pursuant to section 39(2), was above 5 percent of the total share capital and voting rights in Bang & Olufsen A/S.

As of 15 October 2026, UBS Group AG held a total of 7,735,503 shares and voting rights in Bang & Olufsen A/S, corresponding to 5.25 percent of the total share capital and voting rights.

For further information, please contact:

Cristina Rønde Hefting
Sr. Director, Head of Strategy & Investor Relations
Phone: +45 4153 7303

Attachment

Progress on share buyback programme

ING announced today that, as part of our €1.0 billion share buyback programme announced on 30 April 2026, in total 1,000,000 shares were repurchased during the week of 12 October up to and including 16 October 2026.

The shares were repurchased at an average price of €29.96 for a total amount of €29,960,800.00. For detailed information on the daily repurchased shares, individual share purchase transactions and weekly reports, see the updates on the share buyback programme on our website.

In line with the purpose of the programme to reduce the share capital of ING, the total number of shares repurchased under this programme to date is 33,710,805 at an average price of €28.62 for a total consideration of €964,776,200.49. To date approximately 96.48% of the maximum total value of the share buyback programme has been completed.

Note for editors
For further information on ING, please visit www.ing.com. Frequent news updates can be found in the Newsroom. Photos of ING operations, buildings and its executives are available for download at Flickr.

Press enquiries Investor enquiries
ING Group Media Relations ING Group Investor Relations
+31 20 576 5000 +31 20 576 6396
Media.Relations@ing.com Investor.Relations@ing.com

ING PROFILE
ING is a global financial institution with a strong European base, offering banking services through its operating company ING bank. The purpose of ING Bank is: empowering people to stay a step ahead in life and in business. ING Bank’s more than 60,000 employees offer retail and wholesale banking services to customers in over 100 countries.

ING Group shares are listed on the exchanges of Amsterdam (INGA NA, INGA.AS), Brussels and on the New York Stock Exchange (ADRs: ING US, ING.N).

ING aims to put sustainability at the heart of what we do. Our policies and actions are assessed by independent research and ratings providers, which give updates on them annually. ING’s ESG rating by MSCI has been upgraded from ‘AA’ to ‘AAA’ in October 2025. As of July 2026, in Sustainalytics’ view, ING’s management of ESG material risk is ‘Strong’ with an ESG risk rating of 16.7 (low risk). ING Group shares are also included in major sustainability and ESG index products of leading providers. Here are some examples: Euronext, STOXX, Morningstar and FTSE Russell.

IMPORTANT LEGAL INFORMATION
Elements of this press release contain or may contain information about ING Groep N.V. and/ or ING Bank N.V. within the meaning of Article 7(1) to (4) of EU Regulation No 596/2014 (‘Market Abuse Regulation’).

ING Group’s annual accounts are prepared in accordance with International Financial Reporting Standards as adopted by the European Union (‘IFRS- EU’). In preparing the financial information in this document, except as described otherwise, the same accounting principles are applied as in the 2025 ING Group consolidated annual accounts. All figures in this document are unaudited. Small differences are possible in the tables due to rounding.

Certain of the statements contained herein are not historical facts, including, without limitation, certain statements made of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Actual results, performance or events may differ materially from those in such statements due to a number of factors, including, without limitation: (1) changes in general economic conditions and customer behaviour, in particular economic conditions in ING’s core markets, including changes affecting currency exchange rates and the regional and global economic impact of the invasion of Russia into Ukraine and related international response measures (2) changes affecting interest rate levels (3) any default of a major market participant and related market disruption (4) changes in performance of financial markets, including in Europe and developing markets (5) fiscal uncertainty in Europe and the United States (6) discontinuation of or changes in ‘benchmark’ indices (7) inflation and deflation in our principal markets (8) changes in conditions in the credit and capital markets generally, including changes in borrower and counterparty creditworthiness (9) failures of banks falling under the scope of state compensation schemes (10) non-compliance with or changes in laws and regulations, including those concerning financial services, financial economic crimes and tax laws, and the interpretation and application thereof (11) geopolitical risks, political instabilities and policies and actions of governmental and regulatory authorities, including in connection with the invasion of Russia into Ukraine and other existing or emerging military conflicts, the risk of further military escalation, geopolitical tensions, trade restrictions and the related international response measures (12) legal and regulatory risks in certain countries with less developed legal and regulatory frameworks (13) prudential supervision and regulations, including in relation to stress tests and regulatory restrictions on dividends and distributions (also among members of the group) (14) ING’s ability to meet minimum capital and other prudential regulatory requirements (15) changes in regulation of US commodities and derivatives businesses of ING and its customers (16) application of bank recovery and resolution regimes, including write down and conversion powers in relation to our securities (17) outcome of current and future litigation, enforcement proceedings, investigations or other regulatory actions, including claims by customers or stakeholders who feel misled or treated unfairly, and other conduct issues (18) changes in tax laws and regulations and risks of non-compliance or investigation in connection with tax laws, including FATCA (19) operational and IT risks, such as system disruptions or failures, breaches of security, cyber-attacks, human error, changes in operational practices or inadequate controls including in respect of third parties with which we do business and including any risks as a result of incomplete, inaccurate, or otherwise flawed outputs from the algorithms and data sets utilized in artificial intelligence (20) risks and challenges related to cybercrime including the effects of cyberattacks and changes in legislation and regulation related to cybersecurity and data privacy, including such risks and challenges as a consequence of the use of emerging technologies, such as advanced forms of artificial intelligence and quantum computing (21) changes in general competitive factors, including ability to increase or maintain market share (22) inability to protect our intellectual property and infringement claims by third parties (23) inability of counterparties to meet financial obligations or ability to enforce rights against such counterparties (24) changes in credit ratings (25) business, operational, regulatory, reputation, transition and other risks and challenges in connection with climate change, diversity, equity and inclusion and other ESG-related matters, including data gathering and reporting and also including managing the conflicting laws and requirements of governments, regulators and authorities with respect to these topics (26) inability to attract and retain key personnel (27) future liabilities under defined benefit retirement plans (28) failure to manage business risks, including in connection with use of models, use of derivatives, or maintaining appropriate policies and guidelines (29) changes in capital and credit markets, including interbank funding, as well as customer deposits, which provide the liquidity and capital required to fund our operations, and (30) the other risks and uncertainties detailed in the most recent annual report of ING Groep N.V. (including the Risk Factors contained therein) and ING’s more recent disclosures, including press releases, which are available on www.ing.com.

This document may contain ESG-related material that has been prepared by ING on the basis of publicly available information, internally developed data and other third-party sources believed to be reliable. ING has not sought to independently verify information obtained from public and third-party sources and makes no representations or warranties as to accuracy, completeness, reasonableness or reliability of such information. This document may also discuss one or more specific transactions and/or contain general statements about ING’s ESG approach. The approach and criteria referred to in this document are intended to be applied in accordance with applicable law. Due to the fact that there may be different or even conflicting laws, the approach, criteria or the application thereof, could be different.

Materiality, as used in the context of ESG, is distinct from, and should not be confused with, such term as defined in the Market Abuse Regulation or as defined for Securities and Exchange Commission (‘SEC’) reporting purposes. Any issues identified as material for purposes of ESG in this document are therefore not necessarily material as defined in the Market Abuse Regulation or for SEC reporting purposes.  In addition, there is currently no single, globally recognized set of accepted definitions in assessing whether activities are “green” or “sustainable.” Without limiting any of the statements contained herein, we make no representation or warranty as to whether any of our securities constitutes a green or sustainable security or conforms to present or future investor expectations or objectives for green or sustainable investing. For information on characteristics of a security, use of proceeds, a description of applicable project(s) and/or any other relevant information, please reference the offering documents for such security.

This document may contain inactive textual addresses to internet websites operated by us and third parties. Reference to such websites is made for information purposes only, and information found at such websites is not incorporated by reference into this document. ING does not make any representation or warranty with respect to the accuracy or completeness of, or take any responsibility for, any information found at any websites operated by third parties. ING specifically disclaims any liability with respect to any information found at websites operated by third parties. ING cannot guarantee that websites operated by third parties remain available following the publication of this document, or that any information found at such websites will not change following the filing of this document. Many of those factors are beyond ING’s control.

Any forward-looking statements made by or on behalf of ING speak only as of the date they are made, and ING assumes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information or for any other reason.

This document does not constitute an offer to sell, or a solicitation of an offer to purchase, any securities in the United States or any other jurisdiction.

Attachment

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.